The procurement of medicines in national essential drugs are expensive because of access problems. Or is used in patients less of a major buyer has provided the authority to negotiate, however, the odds for a drug with manufacturing, selling only requires new strategies, such as the reference price. value (value-based pricing), if the drug is ineffective. I do not have to pay for her.
การแปล กรุณารอสักครู่..